NVSEF supply chain intelligence for Novartis AG: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Novartis AG (NVSEF) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BIOA | BioAge Labs, Inc. | 85% | Reciprocal relationship from BIOA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BIOA… |
| GLUE | Monte Rosa Therapeutics, Inc. | 85% | Reciprocal relationship from GLUE graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLUE graph: pany has identified certain performance obligations within the agreement as… |
| RGNX | REGENXBIO Inc. | 85% | Reciprocal relationship from RGNX graph: . (Novartis Gene Therapies), a wholly owned subsidiary of Novartis AG (Novartis), for the development and commercialization of treatments for spinal muscular … |
| BNBX | BNB Plus Corp. | 80% | Reciprocal relationship from BNBX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BNBX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BNBX… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ALNY… |
| ANL | Adlai Nortye Ltd. | 72% | Reciprocal relationship from ANL graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ANL graph: asing by US$5 million as a result of advanced payments from customer. Investi… |
| ARE | Alexandria Real Estate Equities, Inc. | 72% | Reciprocal relationship from ARE graph: er Technologies, Inc. 56.5 (4) 1,009,188 27,865 1.5 Baa1 BBB $ 178.6 10 Boston Children's Hospital 11.0 309,231 26,294 1.4 Aa2 AA $ — 11 Novartis AG 2.2 (5) 32… |
| ARGX | argenx SE | 72% | Reciprocal relationship from ARGX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ARGX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ARGX… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $132.7 million and $101.9 million for the three and six months ended March 31, 2026, compared to … |
| BDRX | Biodexa Pharmaceuticals Plc | 72% | Reciprocal relationship from BDRX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BDRX… |
| BNTX | BioNTech SE | 72% | Reciprocal relationship from BNTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BNTX… |
| COLL | Collegium Pharmaceutical, Inc. | 72% | Reciprocal relationship from COLL graph: . At the same time, the Trump Administration has 61 Table of Contents endorsed a federal moratorium on the enforcement of state AI laws, including through a D… |
| CPMV | Mosaic ImmunoEngineering, Inc. | 72% | Reciprocal relationship from CPMV graph: ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third part… |
| CRNX | Crinetics Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CRNX graph: products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement … |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTMX graph: h activities and efforts to establish and run clinical trials for Varseta-M… |
| CTNM | Contineum Therapeutics, Inc. | 72% | Reciprocal relationship from CTNM graph: om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and entities. Violations of Trade Laws can … |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subse… |
| DRTSW | DRTSW | 72% | Reciprocal relationship from DRTSW graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from DRTSW graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from DR… |
| ELVN | Enliven Therapeutics, Inc. | 72% | Reciprocal relationship from ELVN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ELVN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ELVN… |
| ERAS | Erasca, Inc. | 72% | Reciprocal relationship from ERAS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ERAS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ERAS… |
| GKOS | Glaukos Corporation | 72% | Reciprocal relationship from GKOS graph: compete with many companies, including divisions of companies much larger than us that may have greater resources and name recognition, and smaller companies … |
| GLTO | Damora Therapeutics, Inc. | 72% | Reciprocal relationship from GLTO graph: 026, we had an accumulated deficit of $515.1 million. We expect to continue to incur losses for the foreseeable future. Our operating expenses and net losses … |
| HLN | Haleon plc | 72% | Reciprocal relationship from HLN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from HLN graph: long term, related to climate change and our impacts and dependencies on natu… |
| IMNM | Immunome, Inc. | 72% | Reciprocal relationship from IMNM graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from IMNM… |
| INCY | Incyte Corporation | 72% | Reciprocal relationship from INCY graph: (in thousands): December 31, 2024 2023 Raw materials $ 27,590 $ 23,282 API and Work-in-process 331,178 209,793 Finished goods 48,431 36,862 Total inventory $ … |
| IRIX | IRIDEX Corporation | 72% | Reciprocal relationship from IRIX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers suc… |
| JBIO | Jade Biosciences, Inc. | 72% | Reciprocal relationship from JBIO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from JBIO graph: fluctuate significantly from quarter to quarter and year to year. We antici… |
| KLRS | Kalaris Therapeutics, Inc. | 72% | Reciprocal relationship from KLRS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KLRS graph: or through collaborations or other arrangements with third parties. We inte… |
| KMDA | Kamada Ltd. | 72% | Reciprocal relationship from KMDA graph: al forecasts. Customers For the year ended December 31, 2015, sales to Baxalta and Kupat Holim Clalit, an Israeli healthcare provider, accounted for 37% and 1… |
| KYMR | Kymera Therapeutics, Inc. | 72% | Reciprocal relationship from KYMR graph: ons by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could c… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ALNY… |
| BDRX | Biodexa Pharmaceuticals Plc | 72% | Reciprocal relationship from BDRX graph: f these include the following: • We have experienced some delays in our clinical trials, in particular our Phase I trials of MTX110 in diffuse intrinsic ponti… |
| BNBX | BNB Plus Corp. | 72% | Reciprocal relationship from BNBX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BNBX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BNBX… |
| BNTX | BioNTech SE | 72% | Reciprocal relationship from BNTX graph: If and when we receive full marketing authorization for our COVID-19 vaccine, we will market our products through personal interactions with physicians and al… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our work… |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cG… |
| DRTSW | DRTSW | 72% | Reciprocal relationship from DRTSW graph: o binding term sheets with Medison Pharma Ltd., one of the largest commercial partners of leading global biotech companies in international markets, and its … |
| ELVN | Enliven Therapeutics, Inc. | 72% | Reciprocal relationship from ELVN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ELVN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ELVN… |
| EMMA | Emmaus Life Sciences, Inc. | 72% | Reciprocal relationship from EMMA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from EMMA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from EMMA… |
| GERN | Geron Corporation | 72% | Reciprocal relationship from GERN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GERN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GERN… |
| GLTO | Damora Therapeutics, Inc. | 72% | Reciprocal relationship from GLTO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLTO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLTO… |
| GLUE | Monte Rosa Therapeutics, Inc. | 72% | Reciprocal relationship from GLUE graph: delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects. In addition, some of… |
| IMNM | Immunome, Inc. | 72% | Reciprocal relationship from IMNM graph: third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations; government enforcement a… |
| INCY | Incyte Corporation | 72% | Reciprocal relationship from INCY graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from INCY graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from INCY… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | Reciprocal relationship from IOVA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from IOVA… |
| IRIX | IRIDEX Corporation | 72% | Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, … |
| JBIO | Jade Biosciences, Inc. | 72% | Reciprocal relationship from JBIO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from JBIO… |
| KLRS | Kalaris Therapeutics, Inc. | 72% | Reciprocal relationship from KLRS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KLRS… |
| KMDA | Kamada Ltd. | 72% | Reciprocal relationship from KMDA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KMDA graph: approximately 90% of the anti-rabies market in the United States, and CSL, … |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, i… |
| LNTH | Lantheus Holdings, Inc. | 72% | Reciprocal relationship from LNTH graph: ources, raw materials and, for our diagnostic imaging agents, staff at imaging centers and hospitals and PET scanner capacity. For example, for PNT2003, our p… |
| LQDA | Liquidia Corporation | 72% | Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Trepr… |
| MLTX | MoonLake Immunotherapeutics | 72% | Reciprocal relationship from MLTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MLTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MLTX… |
| MREO | Mereo BioPharma Group plc | 72% | Reciprocal relationship from MREO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MREO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MREO… |
| OCS | Oculis Holding AG | 72% | Reciprocal relationship from OCS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from OCS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from OCS gr… |
| OCSAW | OCSAW | 72% | Reciprocal relationship from OCSAW graph: us to fund current planned operations beyond the next twelve months from the date of this Annual Report without additional capital. We have based our estimat… |
| PLRX | Pliant Therapeutics, Inc. | 72% | Reciprocal relationship from PLRX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from PLRX graph: aring dividends. If we raise additional capital through marketing and distr… |
| PTCT | PTC Therapeutics, Inc. | 72% | Reciprocal relationship from PTCT graph: rmaceutical products for which marketing authorization has been granted are subject to extensive and rigorous regulation; ● Failure to obtain and maintain acc… |
| RDY | Dr. Reddy's Laboratories Limited | 72% | Reciprocal relationship from RDY graph: ell lung cancer following the results of the futility analysis. As a result, the Company recorded an impairment loss of Rs. 914 (U.S.$ 10 ) in the consolidated… |
| RNTX | Rein Therapeutics Inc. | 72% | Reciprocal relationship from RNTX graph: development stage. Manufacturing We do not own or operate manufacturing facilities for the production of any of our product candidates, nor do we have plans t… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| NVSEF-DEBT | Debt stack $47.0B | 90% | Market cache reports total debt of $47.0B. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALVO | Alvotech | 100.00 | 2 | |
| GERN | Geron Corporation | 100.00 | 1 | ['customer'] |
| CYTK | Cytokinetics, Incorporated | 100.00 | 1 | ['customer', 'supplier'] |
| GRAL | GRAIL, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| AMGN | Amgen Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 1 | ['customer'] |
| BIOA | BioAge Labs, Inc. | 100.00 | 1 | ['supplier'] |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 1 | ['supplier'] |
| CLX | The Clorox Company | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| BDRX | Biodexa Pharmaceuticals Plc | 100.00 | 1 | ['customer', 'supplier'] |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 1 | ['customer', 'supplier'] |
| DEO | Diageo plc | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 |